Clinical Trials on Refractory Angioimmunoblastic T-Cell Lymphoma in Belgium

Total 292 results

Hoffmann-La Roche

Active, not recruiting

A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma

B-cell Non-Hodgkin Lymphoma

United States, Canada, Belgium, Spain, United Kingdom
Gilead Sciences

Completed

Safety Profile of Idelalisib in Patients With Refractory Follicular Lymphoma (ZEUS)

Follicular Non-Hodgkin's Lymphoma Refractory

Spain, France, Ireland, Italy, Greece, Germany, United Kingdom, Sweden, Belgium, Portugal
ADC Therapeutics S.A.

Completed

Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma

Refractory Hodgkin Lymphoma | Relapsed Hodgkin Lymphoma

United States, Spain, United Kingdom, Poland, Belgium, Hungary, Germany, France, Italy, Czechia, Canada
Hoffmann-La Roche

Recruiting

A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Diffuse Large B-cell Lymphoma

Korea, Republic of, United States, China, Germany, Poland, Spain, Taiwan, United Kingdom, Australia, France, Belgium, Switzerland, Denmark, Puerto Rico
Genmab
AbbVie

Recruiting

Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma (EPCORE DLBCL-3)

Diffuse Large B-Cell Lymphoma

France, Korea, Republic of, Spain, Belgium, Japan, Germany, Czechia, United Kingdom, Italy, Austria, United States, Poland
The Lymphoma Academic Research Organisation
Centre Henri Becquerel

Completed

Efficacy of Lenalidomide in Combination With Subcutaneous Rituximab + miniCHOP in DLBCL Patients of 80 y/o or+

Diffuse Large B Cell Lymphoma

France, Belgium
Spectrum Pharmaceuticals, Inc

Terminated

Study of Zevalin Versus Observation in Participants at Least 60 Years Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in Positron Emission Tomography (PET)-Negative Complete Remission After Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) or R-CHOP-like Therapy

Diffuse Large B-cell Lymphoma | Follicle Center Lymphoma

United States, France, United Kingdom, Ireland, Israel, Belgium, Spain, Netherlands, Australia, Puerto Rico, Canada, Italy, Austria
Amgen

Terminated

Effect of Blinatumomab on Minimal Residual Disease (MRD) in Diffuse Large B-Cell Lymphoma (DLBCL) Subjects Post Autologous Hematopoietic Stem Cell Transplantation (aHSCT)

High-risk Diffuse Large B-cell Lymphoma

United States, Italy, Belgium, Switzerland, Australia, France, Greece
Spectrum Pharmaceuticals, Inc
Bayer

Terminated

Study Comparing Zevalin Regimen With no Further Treatment in Patients With Diffuse Large B-cell Lymphoma.

Lymphoma, Large Cell, Diffuse

Sweden, United States, Italy, Korea, Republic of, Spain, United Kingdom, Hungary, Poland, Finland, Canada, France, Germany, Portugal, Thailand, Belgium, Austria, Ireland, Singapore, Switzerland
MorphoSys AG

Completed

Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL

Diffuse Large B-cell Lymphoma

Belgium, Germany, United States, Austria, Czechia, France, Italy, Portugal, Spain
Hoffmann-La Roche

Active, not recruiting

An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Non-Hodgkins Lymphoma

Belgium, Spain, Denmark, Italy, United Kingdom, Israel, United States
European Organisation for Research and Treatment...
Pfizer

Completed

CREATE: Cross-tumoral Phase 2 With Crizotinib (CREATE)

Locally Advanced and/or Metastatic Anaplastic Large Cell Lymphoma | Locally Advanced and/or Metastatic Inflammatory Myofibroblastic Tumor | Locally Advanced and/or Metastatic Papillary Renal Cell Carcinoma Type 1 | Locally Advanced and/or Metastatic Alveolar Soft Part Sarcoma | Locally Advanced... and other conditions

France, Belgium, Netherlands, Germany, United Kingdom, Italy, Norway, Poland, Slovakia, Slovenia
The Lymphoma Academic Research Organisation

Completed

Study of Mini-Chop Plus Ofatumumab To Treat Cd 20+ Diffuse Large B-Cell Lymphoma In Patients Aged Over 80 Years

Non Previously Treated CD20+ Diffuse Large B-cell Lymphoma

Belgium, France
Pharmacyclics LLC.

Completed

A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Chronic Lymphocytic Leukemia | Small-Cell Lymphoma

United States, Australia, Austria, Belgium, Canada, Czechia, France, Israel, Italy, New Zealand, Poland, Russian Federation, Spain, Sweden, Turkey, United Kingdom
Genmab
AbbVie

Active, not recruiting

A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in R/R DLBCL (EPCORE DLBCL-1)

Diffuse Large B-cell Lymphoma

Korea, Republic of, Spain, Taiwan, Belgium, France, Israel, United Kingdom, China, United States, Netherlands, Japan, Sweden, Turkey, Australia, Singapore, Germany, Denmark, Poland, Italy, Hungary, Austria, Russian Federation, Norway, Canad... and more
The Lymphoma Academic Research Organisation
Hoffmann-La Roche

Terminated

GA In NEwly Diagnosed Diffuse Large B Cell Lymphoma (GAINED)

Diffuse Large B Cell Lymphoma CD20 Positive

France, Belgium
Incyte Corporation

Active, not recruiting

A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL) (topMIND)

Chronic Lymphocytic Leukemia | Non Hodgkin Lymphoma

United States, Spain, France, Italy, Belgium, Germany, Austria
Hoffmann-La Roche

Recruiting

A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of RO7227166 in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab Administered in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Lymphoma, Non-Hodgkin

United States, Belgium, Australia, Denmark, Italy, Spain, France, United Kingdom
University Hospital Muenster
Deutsche Krebshilfe e.V., Bonn (Germany)

Recruiting

International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma (LBL 2018)

Lymphoblastic Lymphoma, Childhood

Spain, Austria, Denmark, Finland, Germany, Belgium, Switzerland, China, Czechia, France, Hungary, Ireland, Israel, Italy, Netherlands, Norway, Poland, Portugal, Russian Federation, Slovakia, Sweden
Pharmacyclics LLC.
Janssen Research & Development, LLC

Completed

Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States, Australia, Belgium, Canada, China, Czechia, Ireland, Israel, Italy, New Zealand, Poland, Russian Federation, Spain, Turkey, Ukraine, United Kingdom
Regeneron Pharmaceuticals

Recruiting

A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Patients With Previously Untreated Diffuse Large B-cell Lymphoma (OLYMPIA-3)

Diffuse Large B-cell Lymphoma (DLBCL)

United States, Spain, Korea, Republic of, Italy, Belgium, Austria, Thailand, Singapore, Turkey, France, Israel, Australia, Czechia, Poland, Chile, United Kingdom, Germany
CTI BioPharma

Completed

Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant (PIX-R)

Diffuse Large B-cell Lymphoma | de Novo DLBCL | DLBCL Transformed From Indolent Lymphoma | Follicular Grade 3 Lymphoma

United States, Germany, Italy, United Kingdom, Hungary, France, Spain, Ukraine, Czechia, Austria, Belgium, Bulgaria, Denmark, Poland, Romania, Russian Federation, Slovakia
Acerta Pharma BV

Active, not recruiting

An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma

Mantle Cell Lymphoma (MCL)

Belgium, France, United Kingdom, United States, Italy, Poland, Netherlands, Australia, Czechia, Spain
The Lymphoma Academic Research Organisation

Completed

Study of Lenalidomide Maintenance Versus Placebo in Responding Elderly Patients With DLBCL and Treated With R-CHOP (REMARC)

Lymphoma | Diffuse Large B-cell Lymphoma

Belgium, Switzerland, France, Australia, Spain, Israel, Austria, Portugal, Poland
The Lymphoma Academic Research Organisation
Daiichi Sankyo

Active, not recruiting

Study of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphoma

Lymphoma, B-Cell

France, Belgium
International BFM Study Group
European Organisation for Research and Treatment of Cancer - EORTC; Associazione... and other collaborators

Completed

Pulses of Vincristine and Dexamethasone in BFM Protocols for Children With Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia

Germany, Argentina, Austria, Belgium, Chile, Czech Republic, Hungary, Italy
Epizyme, Inc.

Enrolling by invitation

A Study to Assess the Long-term Safety of Tazemetostat (TRuST)

Advanced Solid Tumors | Mesothelioma | Synovial Sarcoma | Renal Medullary Carcinoma | Diffuse Large B-cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Non-Hodgkin Lymphoma (NHL) | Epitheliod Sarcoma (ES)

United States, France, United Kingdom, Poland, Australia, Belgium, Ukraine
International Extranodal Lymphoma Study Group (IELSG)

Active, not recruiting

MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas (MALIBU)

Splenic Marginal Zone Lymphoma | Marginal Zone Lymphoma | Nodal Marginal Zone Lymphoma

France, Switzerland, Italy, Belgium, Portugal
Seagen Inc.

Active, not recruiting

Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL (ECHELON-3)

Diffuse Large B-cell Lymphoma

United States, France, Australia, Czechia, Italy, Spain, Canada, Belgium, Korea, Republic of, United Kingdom, Poland, Denmark, Germany, Netherlands, Switzerland, Taiwan
Janssen Research & Development, LLC
Pharmacyclics LLC.

Completed

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States, France, Poland, Belgium, Germany, Spain, Argentina, Colombia, Israel, Portugal, Russian Federation, Turkey, Ukraine, Canada, Greece, Sweden, Korea, Republic of, United Kingdom, Brazil, Mexico, Czechia
Incyte Corporation

Completed

A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202)

Lymphoma

United States, Spain, Korea, Republic of, Belgium, Australia, Czechia, Poland, Canada, France, Italy, United Kingdom
Amgen

Completed

Study to Evaluate Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory (R/R) Aggressive B-Cell NHL

B-Cell Non Hodgkin Lymphoma

United States, Spain, United Kingdom, Belgium, Italy, Australia, Canada, Puerto Rico
Karyopharm Therapeutics Inc

Recruiting

Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Diffuse Large B-cell Lymphoma

United Kingdom, United States, Australia, Austria, Belgium, Bulgaria, Canada, France, Germany, Greece, Hungary, India, Israel, Italy, Netherlands, New Zealand, Poland, Serbia, Spain
GlaxoSmithKline

Completed

Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma (ORCHARRD)

Lymphoma, Large-Cell, Diffuse

United States, Netherlands, Estonia, Spain, United Kingdom, Sweden, Israel, Poland, Belgium, Korea, Republic of, Singapore, Austria, Germany, Finland, Ireland, Thailand, China, Russian Federation, Czech Republic, Argentina, Denmark and more
European Organisation for Research and Treatment...
Acute Leukemia French Association

Completed

Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Lymphoblastic Leukemia

Lymphoma | Leukemia

France, Belgium, Netherlands, Italy, Czech Republic, Portugal, Croatia, Turkey, Germany, Slovakia
University of Liege
University Hospital, Ghent; AZ Sint-Jan AV; Cliniques universitaires Saint-Luc-... and other collaborators

Terminated

MSC and HSC Coinfusion in Mismatched Minitransplants

Lymphoma, Non-Hodgkin | Myelodysplastic Syndromes | Leukemia, Myeloid, Acute | Myeloproliferative Disorders | Multiple Myeloma | Leukemia, Lymphoblastic, Acute | Hodgkin's Disease | Leukemia, Lymphocytic, Chronic | Leukemia, Myelocytic, Chronic

Belgium
Janssen Research & Development, LLC
Pharmacyclics LLC.

Enrolling by invitation

A Long-term Extension Study of PCI-32765 (Ibrutinib) (CAN3001)

Follicular Lymphoma | Chronic Graft Versus Host Disease | Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large B-cell Lymphoma | Small Lymphocytic Lymphoma

United States, Spain, United Kingdom, Israel, Canada, Belgium, Poland, China, Japan, France, Australia, Russian Federation, Turkey, Sweden, Italy, Mexico, Czechia, Korea, Republic of, Ukraine, Brazil, Hungary, Portugal, Argentina, Col... and more
Celgene
Juno

Withdrawn

A Study to Determine Safety, Feasibility and Efficacy of JCAR015 in Adult Subjects With B-Cell Acute Lymphoblastic Leukemia (ORBIT)

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Belgium, France, Spain, Italy, Germany, Switzerland, United Kingdom
Hoffmann-La Roche

Completed

A Study of Subcutaneous Versus Intravenous MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in Patients With Previously Untreated CD20-Positive Diffuse Large B-Cell Lymphoma

Lymphoma, Large B-Cell, Diffuse

Italy, Belgium, Canada, Finland, Ireland, Netherlands, Peru, Spain, United Kingdom, Venezuela, Russian Federation, Brazil, France, Poland, Israel, South Africa, Thailand, Bulgaria, Colombia, Greece, Turkey, Argentina, Saudi Arabia, Uk... and more
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Terminated

Phase I/II Study of Avelumab in Pediatric Cancer Participants

Lymphoma | Refractory or Relapsed Solid Tumors

Korea, Republic of, United States, Canada, Belgium, Denmark
Janssen Research & Development, LLC
Pharmacyclics LLC.

Completed

A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma

Lymphoma

United States, Australia, France, Poland, United Kingdom, China, Belgium, Germany, Spain, Israel, Turkey, Ukraine, Japan, Taiwan, Canada, Denmark, Finland, Korea, Republic of, Netherlands, Brazil, Russian Federation, Argentina, Norway, Swed... and more
Stichting Hemato-Oncologie voor Volwassenen Nederland

Active, not recruiting

Blinatumomab Added to Prephase and Consolidation Therapy in Precursor B-acute Lymphoblastic Leukemia in Adults. (HOVON146ALL)

ALL, Adult

Netherlands, Belgium
The Lymphoma Academic Research Organisation
Institute of Cancer Research, United Kingdom

Recruiting

Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma

Mantle Cell Lymphoma

France, United Kingdom, Belgium
SecuraBio

Completed

A Phase 3 Extension Study of Duvelisib and Ofatumumab in Participants With CLL/SLL Previously Enrolled in Study IPI-145-07

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

Belgium, France, Italy, Spain, United States, Austria, New Zealand, Hungary, United Kingdom, Australia, Germany
Celgene

Withdrawn

Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma

Lymphoma, B-Cell

Korea, Republic of, United States, Spain, Belgium, Taiwan, United Kingdom, Austria, France
Genmab
AbbVie

Recruiting

Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome (EPCORE™ CLL-1)

Small Lymphocytic Lymphoma | Richter's Syndrome | Relapsed/Refractory Chronic Lymphocytic Leukemia

United States, Belgium, Netherlands, Spain, Italy, Australia, Israel, France, Denmark, Czechia, Germany, United Kingdom
Universitaire Ziekenhuizen KU Leuven

Unknown

Genomic Analysis of Patients With Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

Belgium
Pharmacyclics LLC.
Janssen Research & Development, LLC

Completed

A Multicenter Phase 2 Study of Ibrutinib in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p Deletion

Chronic Lymphocytic Leukemia With 17p Deletion | Small Lymphocytic Lymphoma With 17p Deletion

United States, United Kingdom, Belgium, Germany, Turkey, Australia, Canada, New Zealand, Sweden
Celgene

Completed

Trial to Determine the Efficacy and Safety of JCAR017 in Adult Participants With Aggressive B-Cell Non-Hodgkin Lymphoma (TRANSCENDWORLD)

Lymphoma, Non-Hodgkin

Italy, Switzerland, Austria, Belgium, France, Germany, Japan, Netherlands, Spain, United Kingdom, Finland
Celgene

Completed

Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma (ROBUST)

Lymphoma, Large B-Cell, Diffuse

United States, Australia, Belgium, Canada, China, Czechia, France, Ireland, Israel, Italy, Japan, Korea, Republic of, Netherlands, New Zealand, Portugal, Puerto Rico, Russian Federation, Spain, Switzerland, Taiwan, Turkey

Clinical Trials on Refractory Angioimmunoblastic T-Cell Lymphoma in Belgium

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Thailand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations